ZYNE Key Statistics, Chart & Performance
The current stock price of ZYNE is 1.3 USD. In the past month the price decreased by -1.52%. In the past year, price increased by 89.61%.
ZYNE Latest News, Press Relases and Analysis
ZYNE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47 | 977.11B | ||
| JNJ | JOHNSON & JOHNSON | 19.78 | 494.70B | ||
| MRK | MERCK & CO. INC. | 11.61 | 253.84B | ||
| PFE | PFIZER INC | 7.99 | 145.38B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.77 | 103.74B | ||
| ZTS | ZOETIS INC | 19.33 | 54.02B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.64 | 22.86B | ||
| VTRS | VIATRIS INC | 4.65 | 12.49B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.1 | 11.02B | ||
| CORT | CORCEPT THERAPEUTICS INC | 95.08 | 8.80B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.45B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.30B |
Related stock screener links
About ZYNE
Company Profile
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. The company is headquartered in Devon, Pennsylvania and currently employs 25 full-time employees. The company went IPO on 2015-08-05. The firm is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). The company is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. The company is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). The company uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).
Company Info
ZYNERBA PHARMACEUTICALS INC
80 W. Lancaster Avenue, Suite 300
Devon PENNSYLVANIA 19333 US
CEO: Armando Anido
Employees: 25
Phone: 14845817505.0
ZYNERBA PHARMACEUTICALS INC / ZYNE FAQ
What does ZYNE do?
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. The company is headquartered in Devon, Pennsylvania and currently employs 25 full-time employees. The company went IPO on 2015-08-05. The firm is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). The company is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. The company is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). The company uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).
Can you provide the latest stock price for ZYNERBA PHARMACEUTICALS INC?
The current stock price of ZYNE is 1.3 USD. The price increased by 2.36% in the last trading session.
What is the dividend status of ZYNERBA PHARMACEUTICALS INC?
ZYNE does not pay a dividend.
What is the ChartMill technical and fundamental rating of ZYNE stock?
ZYNE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is ZYNERBA PHARMACEUTICALS INC (ZYNE) stock traded?
ZYNE stock is listed on the Nasdaq exchange.
Can you provide the market cap for ZYNERBA PHARMACEUTICALS INC?
ZYNERBA PHARMACEUTICALS INC (ZYNE) has a market capitalization of 70.12M USD. This makes ZYNE a Micro Cap stock.
ZYNE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ZYNE. When comparing the yearly performance of all stocks, ZYNE is one of the better performing stocks in the market, outperforming 99.66% of all stocks.
ZYNE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZYNE. While ZYNE seems to be doing ok healthwise, there are quite some concerns on its profitability.
ZYNE Financial Highlights
Over the last trailing twelve months ZYNE reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 13.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -92.85% | ||
| ROE | -129.5% | ||
| Debt/Equity | 0 |
ZYNE Forecast & Estimates
9 analysts have analysed ZYNE and the average price target is 1.28 USD. This implies a price decrease of -1.53% is expected in the next year compared to the current price of 1.3.